A bill aimed at reining in the outsize power of pharmacy benefit managers made it to the governor’s desk for naught.

From a valuation perspective, the stock is inexpensive, trading at a forward price-to-earnings (P/E) of about 8.4 times based ...

Texas is the latest state to join the legal fight with drug manufacturers and pharmacy benefit managers over the cost of ...

PBMs charge insurance plans more for a prescription drug than what is paid to the pharmacy for the medication and keep the ...

The state alleges this insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment ...

The state of Texas has filed a lawsuit against drug companies that produce insulin and pharmacy benefit managers (PBM), claiming there is a conspiracy to k ...

Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...

The litigation comes as pharmacy benefit managers Express Scripts, CVS Caremark and Optum Rx have faced growing criticism over their role in high drug costs — including a recent lawsuit from the ...

Texas Attorney General Ken Paxton has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers over an alleged conspiracy to increase i ...

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...

The government bill for the law might mean less cash will be saved than hoped, Stat reports. The Medicare Part D drug benefit is estimated to cost $10 billion to $20 billion more in 2025 than ...

The Federal Trade Commission's new lawsuit against big pharmaceutical "middlemen" threatens to disrupt a system that has been ...